



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

**** Wednesday November 12, 2008 6:30 – 9:00 p.m. ****

PLEASE NOTE DATE/DAY CHANGE

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:25**
 - Clinical Programs Update
 - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:25 - 7:25**
 - No items
- 6. Clinical Update: Drug Reviews** **7:25 – 7:40**

(Public comment prior to Board action)

 - Cimzia® (certolizumab pegol) Subcutaneous Injection
 - Patanase® (olopatadine) Intranasal Spray
- 7. Annual Review of Clinical Coverage Criteria** **7:40 – 8:30**

Class review documents available on OVHA web site 11/12/08 @ 12 Noon

(Public comment prior to Board action)

 - Anti-hyperkinesia and Anti-narcolepsy (**no changes proposed**)
 - Anti-anxiety: Anxiolytics (**no changes proposed**)
 - Sedative/Hypnotics: Benzodiazepine (**no changes proposed**)
 - Sedative/Hypnotics: Non-Benzodiazepine (**proposed preferred drug change**)
 - Antidepressant Class Reviews (**no changes proposed to 4 sub-classes below**)
 - Miscellaneous
 - SNRIs
 - SSRIs
 - Tricyclics & MAOIs
- 8. Drug Classes – New** **8:30 – 8:40**
 - Testosterone: Topical

| | |
|--|--------------------|
| 9. RetroDUR | 8:40 - 8:40 |
| ▪ No RetroDUR this month | |
| 10. New Drug Product Plan Exclusions (Consent Agenda Topic) | 8:40 - 8:45 |
| 11. Updated New-to-Market Drug Monitoring Log | 8:45 - 8:50 |
| 12. General Announcements | 8:50 - 9:00 |
| Selected FDA Safety Alerts | |
| ▪ Over the Counter Cough and Cold Medications | |
| ▪ Raptiva® (efalizumab) – life-threatening infections | |
| 13. Adjourn | 9:00 |
| 14. | |